Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific equity transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific share option exercise by Dr. P J T Vallance on December 1, 2011, involving the purchase of 1,009 Ordinary shares at a price of £9.51 per share under the Sharesave Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly adheres to Disclosure Rule 3.1.4R(1)(a) regarding the notification of the director's transaction.
Investor Verification Points
- Verify the total number of shares outstanding and the impact of the 1,009 share exercise on Dr. Vallance's total holdings.
- Confirm the current market price of GSK Ordinary shares relative to the £9.51 exercise price to assess the immediate economic gain.
- Review the full annual report (Form 20-F) for comprehensive financial performance data for the 2011 fiscal year, as this 6-K does not include it.